Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Joe E. who wrote (3419)	12/28/1997 9:56:00 PM
From: billkirn	Respond to of 6136

Joe: I like to focus on a few companies. And I see the Rouche pull out as adding considerable risk to Agrouron. If they will find another partner for AG3340 adn AG2043 I will feel more secure. Did you see my note on Lilly's exit from their GART inhibitor. This adds even more risk that another effort my go down the tubes again raising the risk they will soon find another successful drug to follow Viracept. I think these factors are why the stock fell almost 50%. As they make progress over this next year, I hope the stock will reflect it. Bill